![]() ![]() ![]() My nonprofit, Partners in Opportunity, is looking for someone to serve as our Family Support Director in the Dallas-Fort Worth area. I learned a lot from him. The only downside of working with Charlie is that when I would come up with what I thought was a great idea, he would say something like, “Back in 1962, I worked on…” and then he would dig through his very cluttered office and pull out of a box or drawer a (very old) inhaler prototype of the very concept I thought I was inventing! That was a very small price to pay for having the opportunity to learn from a great scientist. Charlie was a mentor to me and was a good friend. He will be missed. I and my colleagues at 3M/Kindeva were very fortunate to have had the opportunity to work with and learn from Charlie. Charlie received the highest recognition for scientific excellence at 3M when he was granted membership into the Carlton Society in 1982. After ‘retiring’ from 3M, Charlie continued to contribute to our industry through his participating on the USP on the Aerosol Experts Committee. In 2017, Charlie received the inaugural USP Jacob Bigelow Award in recognition of his dedication and exemplary leadership to the USP Aerosols Expert Committee ( ). Thiel Award is given every other year to a scientist working in the field of inhaler development as a kind of lifetime achievement award in our field. Deservingly, Charlie was given the initial “Charlie” award at the Respiratory Drug Delivery conference in 2006. The two companies will jointly identify clinical development candidates, after which Astellas will have an exclusive option to licence the rights for further development and commercialisation of any discovered compounds.It is with sadness that I share that Charlie Thiel passed away on Friday, March 10, 2023. Charlie was in his mid-90s. Charlie was an inventor who helped develop the first metered dose inhalers (MDIs) back in 1956 with Riker Laboratories (later 3M Drug Delivery Systems, now Kindeva). Charlie’s impact in our industry and our society is noteworthy. Thousands of people take doses from their MDI every second and almost certainly millions of lives have been saved because of the invention of the MDI.Ĭharlie’s impact in our industry is so legendary that the Charles G. The partnership, which is worth up to $1.9bn, will utilise Cullgen’s uSMITE targeted protein degradation platform, featuring novel E3 ligands, alongside Astellas' drug discovery capabilities. The deal comes just less than a month after Astellas and Cullgen entered into a research collaboration and exclusive option agreement aimed at advancing targeted protein degraders. “This collaboration with Astellas, a leader in AAV gene therapy, continues to validate R100 for routine intravitreal low dose delivery of genetic payloads for the treatment of retinal diseases,” he said.Īdam Pearson, chief strategy officer at Astellas, said: "We believe that this collaboration will bring synergies between the two companies' cutting-edge research, and will ultimately lead to the development of new therapeutics for patients with ophthalmic diseases at high risk of blindness.” The Japanese drugmaker will be responsible for all research, development, manufacturing, and commercialisation activities for the resulting programmes.ĭavid Kirn, co-founder and chief executive officer of 4DMT, outlined that over 70 patients have been dosed with R100-based product candidates in wet age-related macular degeneration and rare ophthalmic diseases. According to the companies, it "has the ability to penetrate the internal limiting membrane barrier and to efficiently transduce the entire retina, resulting in robust transgene expression within retinal cells".Īstellas will use the vector initially for one genetic target implicated in rare monogenic ophthalmic diseases and will have the option to add up to two more targets after paying additional option exercise fees. R100 is an adeno-associated virus vector invented by 4DMT for intravitreal delivery. Under the terms of the licensing agreement, the US genetic medicines company will receive an upfront payment of $20m in exchange for its proprietary R100 vector technology and will also be eligible for future option fees and milestones of up to $942.5m plus certain royalties. Astellas Pharma has said it will be gaining the rights to use one of 4D Molecular Therapeutics’ (4DMT) gene therapy vectors for at least one rare eye disease. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |